Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for evidence in the transcript. The transcript is from Zenvia's Q4 2021 earnings call. Management discusses growth, acquisitions, product launches, etc. We need to see if they mention that the size of deals or contracts is escalating. Let's scan the transcript for relevant statements. Cassio Bobsin, CEO, and Shay Chor, IR, speak. They talk about revenue growth, organic growth, client base, net revenue retention, etc. They mention that they are moving from SMS termination to SaaS solutions. They talk about integration of acquisitions. Specifically, we need to find if they say that new deals are bigger than before. For example, they might say that customers are starting with larger contracts, or that they are expanding from single use cases to broader engagements. Let's look for phrases like "larger deals", "bigger contracts", "expanding scope", "upsell", "cross-sell", "land and expand", etc. In the prepared remarks, Cassio says: "We initially adopt alarm and expand strategy in which we introduce our platform based on one simple use case, and then develop the customer relationship over time by upsell and cross selling." That is about land and expand, but it doesn't necessarily say that the initial deals are getting bigger. It says they start with a simple use case and then expand. That is about the strategy, not about escalation of initial deal size. Later, they talk about the integration of acquisitions and how they are moving customers from base communication processes to journey-wide implementations. But that is about the product offering, not necessarily about deal size. We need to see if they explicitly say that the average deal size is increasing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.